VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update
VolitionRx reported Q1 2026 revenue of $1.0 million, a 400% increase year-over-year from $0.2 million, driven by early commercial activity and licensing discussions. The company raised approximately $7.3 million in total capital during the quarter, including $5.4 million from at-the-market equity sales, $1.9 million from a convertible note, and $1.0 million in non-dilutive grants from the Walloon Region.
Key figures
- Revenue
- 1000000
- Revenue Yoy
- 400%
- Atm equity proceeds
- 5400000
- Operating loss change
- -3%
- Grant funding expected
- 900000
- Grant funding received
- 1000000
- Net cash used operating
- 5300000
- Convertible note proceeds
- 1900000
- Potential milestone payment
- 5000000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.